文献速递糖尿病

2型糖尿病患者中三甲胺N-氧化物与不良肾脏结局及全因死亡率的关联

Association Between Trimethylamine N-oxide and Adverse Kidney Outcomes and Overall Mortality in Type 2 Diabetes Mellitus.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

本研究纳入440例2型糖尿病患者,于2016年10月至2020年6月招募并每3个月随访至2021年12月,采用液相色谱-质谱法检测空腹血清TMAO水平。中位随访4年期间,26例(5.9%)出现血肌酐加倍或进展至需透析的终末期肾病;经倾向评分加权后,血清TMAO最高三分位(≥0.88 μM)患者血肌酐加倍或进展至ESKD的风险为最低三分位的6.45倍,肾功能快速下降风险为5.86倍,且TMAO逐步升高与全因死亡率相关。

要点

  • 血清TMAO最高三分位(≥0.88 μM)患者血肌酐加倍或进展至ESKD风险为最低三分位的6.45倍。
  • 血清TMAO最高三分位患者肾功能快速下降风险为最低三分位的5.86倍。
  • 血清TMAO逐步升高与全因死亡率相关。

核心结论

  • 循环TMAO水平升高的2型糖尿病患者血肌酐加倍、进展至ESKD及死亡的风险更高。
  • TMAO是2型糖尿病患者肾功能进展和死亡风险的潜在生物标志物。

研究设计与样本

  • 研究于2016年10月至2020年6月招募2型糖尿病患者,每3个月监测一次至2021年12月。
  • 共纳入440例2型糖尿病患者,采用液相色谱-质谱法检测血清TMAO水平。
  • 主要肾脏结局为血肌酐加倍或进展至需透析的终末期肾病;次要肾脏结局为2年内估算肾小球滤过率快速下降30%;同时评估全因死亡率。

主要发现

  • 血清TMAO最高三分位(≥0.88 μM)患者年龄更大、糖尿病病程更长、血尿素氮升高、估算肾小球滤过率更低。
  • 中位随访4年期间,26例(5.9%)出现血肌酐加倍或进展至需透析的终末期肾病。
  • 经倾向评分加权后,血清TMAO最高三分位患者血肌酐加倍或进展至ESKD的风险为最低三分位的6.45倍。
  • 经倾向评分加权后,血清TMAO最高三分位患者肾功能快速下降的风险为最低三分位的5.86倍。
  • 血清TMAO逐步升高与全因死亡率相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Type 2 diabetes (T2D) is the major contributor to chronic kidney disease and end-stage kidney disease (ESKD). The influence of trimethylamine N-oxide (TMAO) on kidney outcomes in T2D remains unclear. OBJECTIVE: To examine the association between fasting serum TMAO levels and adverse kidney outcomes in patients with T2D. METHODS: Between October 2016 and June 2020, patients with T2D were recruited and monitored every 3 months until December 2021. Serum TMAO levels were assessed using liquid chromatography-mass spectrometry. The primary kidney outcomes were doubling of serum creatinine levels or progression to ESKD necessitating dialysis; the secondary kidney outcome was a rapid 30% decline in estimated glomerular filtration rate within 2 years. All-cause mortality was also evaluated. RESULTS: Among the 440 enrolled patients with T2D, those in the highest serum TMAO tertile (≥0.88 μM) were older, had a longer diabetes duration, elevated blood urea nitrogen, and lower estimated glomerular filtration rate. Over a median follow-up period of 4 years, 26 patients (5.9%) had a doubling of serum creatinine level or progression to ESKD. After propensity score weighting, the patients in the highest serum TMAO tertile had a 6.45-fold increase in the risk of doubling of serum creatinine levels or progression to ESKD and 5.86-fold elevated risk of rapid decline in kidney function compared with those in the lowest tertile. Additionally, the stepwise increase in serum TMAO was associated with all-cause mortality. CONCLUSION: Patients with T2D with elevated circulating TMAO levels are at higher risk of doubling serum creatinine, progressing to ESKD, and mortality. TMAO is a potential biomarker for kidney function progression and mortality in patients with T2D.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yu PS, Wu PH, Hung WW, et al. Association Between Trimethylamine N-oxide and Adverse Kidney Outcomes and Overall Mortality in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2024. PMID: 38267025. doi:10.1210/clinem/dgae009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。